Shanghai Rendu Biotechnology Co. Ltd. A
Shanghai Rendu Biotechnology Co., Ltd. engages in the research, development, production, and sales of RNA molecular diagnostic technology and products. It offers products in the areas of reproductive health, bloodborne infections, respiratory infections, enterovirus infections, cancer early detection, and other areas; and AutoSAT, SuperSAT, and ultrasonic homogenizer. The company was founded in 2… Read more
Shanghai Rendu Biotechnology Co. Ltd. A - Asset Resilience Ratio
Shanghai Rendu Biotechnology Co. Ltd. A (688193) has an Asset Resilience Ratio of 55.11% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Shanghai Rendu Biotechnology Co. Ltd. A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Rendu Biotechnology Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥542.82 Million | 55.11% |
| Total Liquid Assets | CN¥542.82 Million | 55.11% |
Asset Resilience Insights
- Very High Liquidity: Shanghai Rendu Biotechnology Co. Ltd. A maintains exceptional liquid asset reserves at 55.11% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Rendu Biotechnology Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Shanghai Rendu Biotechnology Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Shanghai Rendu Biotechnology Co. Ltd. A (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Shanghai Rendu Biotechnology Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 51.39% | CN¥510.96 Million | CN¥994.36 Million | +46.63pp |
| 2023-12-31 | 4.76% | CN¥50.21 Million | CN¥1.05 Billion | -44.01pp |
| 2022-12-31 | 48.77% | CN¥530.98 Million | CN¥1.09 Billion | +31.60pp |
| 2019-12-31 | 17.17% | CN¥32.12 Million | CN¥187.07 Million | -- |